Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
19331512
DOI
10.33549/physiolres.931610
PII: 1610
Knihovny.cz E-resources
- MeSH
- Diabetes Mellitus, Type 2 drug therapy metabolism MeSH
- Energy Metabolism drug effects MeSH
- Fibroblast Growth Factors adverse effects metabolism therapeutic use MeSH
- Hypoglycemic Agents adverse effects therapeutic use MeSH
- Anti-Obesity Agents adverse effects therapeutic use MeSH
- Humans MeSH
- Disease Models, Animal MeSH
- Obesity drug therapy metabolism MeSH
- Signal Transduction drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- fibroblast growth factor 21 MeSH Browser
- Fibroblast Growth Factors MeSH
- Hypoglycemic Agents MeSH
- Anti-Obesity Agents MeSH
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator produced primarily by the liver that exerts potent antidiabetic and lipid-lowering effects in animal models of obesity and type 2 diabetes mellitus. This hormone contributes to body weight regulation and is strongly involved in the response to nutritional deprivation and ketogenic state in mice. The principal sites of metabolic actions of FGF21 are adipose tissue, liver and pancreas. Experimental studies have shown marked improvements in diabetes compensation and dyslipidemia after FGF21 administration in diabetic mice and primates. Positive metabolic actions of FGF21 without the presence of apparent side effects make this factor a hot candidate to treat type 2 diabetes and accompanying metabolic diseases. The aim of this review is to summarize the current knowledge about the metabolic effects of FGF21 including some preliminary data on changes of its levels in humans with a special emphasis on its therapeutic potential in type 2 diabetes mellitus.
References provided by Crossref.org
